Wall Street brokerages predict that Celsion Co. (NASDAQ:CLSN) will post $130,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Celsion’s earnings. Celsion also reported sales of $130,000.00 in the same quarter last year. The firm is scheduled to announce its next quarterly earnings results on Friday, April 3rd.
On average, analysts expect that Celsion will report full-year sales of $420,000.00 for the current year, with estimates ranging from $250,000.00 to $510,000.00. For the next year, analysts anticipate that the firm will report sales of $500,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Celsion.
Celsion (NASDAQ:CLSN) last released its quarterly earnings results on Friday, November 15th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.05. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative return on equity of 57.46% and a negative net margin of 1,653.20%.
An institutional investor recently raised its position in Celsion stock. Vanguard Group Inc. increased its stake in shares of Celsion Co. (NASDAQ:CLSN) by 43.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 704,651 shares of the biotechnology company’s stock after purchasing an additional 211,779 shares during the period. Vanguard Group Inc. owned approximately 3.44% of Celsion worth $1,282,000 as of its most recent SEC filing. Institutional investors own 5.95% of the company’s stock.
Celsion stock opened at $1.32 on Friday. The stock’s 50 day moving average price is $1.53 and its 200 day moving average price is $1.74. The firm has a market capitalization of $30.72 million, a PE ratio of -1.94 and a beta of 1.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.58 and a current ratio of 2.58. Celsion has a one year low of $1.05 and a one year high of $2.63.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Featured Article: What is the Beige Book?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.